Michael T Milano1, Manju Sharma2, Scott G Soltys3, Arjun Sahgal4, Kenneth Y Usuki2, Jon-Michael Saenz2, Jimm Grimm5, Issam El Naqa6. 1. Department of Radiation Oncology, University of Rochester, Rochester, New York. Electronic address: michael_milano@urmc.rochester.edu. 2. Department of Radiation Oncology, University of Rochester, Rochester, New York. 3. Department of Radiation Oncology, Stanford University Medical Center, Stanford, California. 4. Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. 5. Department of Radiation Oncology & Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland. 6. Department of Radiation Oncology, University of Michigan Hospital, Ann Arbor, Michigan.
Abstract
PURPOSE: Potential dosimetric and clinicopathologic predictors of radiation-induced brain edema after single-fraction or multifraction stereotactic radiosurgery (SRS) for non-base of skull (non-BOS) meningiomas are summarized based on a systematic review of the published literature. METHODS AND MATERIALS: Reviewed studies (PubMed indexed from 1998 through 2017) included all or some non-BOS meningioma patients, reported risks of edema after SRS, and correlated dosimetric and/or nondosimetric measures with the magnitude of risk. RESULTS: Twenty-six studies reporting risks of edema after SRS for meningioma are reviewed. The treatment techniques as well as distribution of tumor locations, target dosing, and target volume varied across studies. Among 13 studies that included only non-BOS tumors or separately grouped non-BOS tumors, symptomatic edema occurred in 5% to 43% of patients and any edema occurred in 28% to 50%. The reported average time to onset of edema ranged from approximately 3 to 9 months in most studies. Factors reported to significantly correlate with increased risks of edema and/or symptomatic edema after SRS for meningioma include the following: greater tumor margin and/or maximum dose, greater tumor size and/or volume, non-BOS (particularly parasagittal) location, no prior resection for meningioma, and presence of pretreatment edema. Nevertheless, the extent and significance of these factors were inconsistent across studies. Potentially important dosimetric factors, such as volume of brain or tissue receiving single-fraction doses > 10 to 12 Gy, are not well studied. CONCLUSIONS: The variability in risks of edema and in factors impacting those risks is likely a result of differences across studies in the clinicopathologic characteristics of the patient populations, as well as differences in treatment modalities and SRS planning and delivery parameters. More studies on pooled populations, grouped by potential prognostic factors such as tumor location and prior therapy, are needed to better understand dosimetric and nondosimetric factors predictive of edema risk after SRS for meningioma.
PURPOSE: Potential dosimetric and clinicopathologic predictors of radiation-induced brain edema after single-fraction or multifraction stereotactic radiosurgery (SRS) for non-base of skull (non-BOS) meningiomas are summarized based on a systematic review of the published literature. METHODS AND MATERIALS: Reviewed studies (PubMed indexed from 1998 through 2017) included all or some non-BOS meningiomapatients, reported risks of edema after SRS, and correlated dosimetric and/or nondosimetric measures with the magnitude of risk. RESULTS: Twenty-six studies reporting risks of edema after SRS for meningioma are reviewed. The treatment techniques as well as distribution of tumor locations, target dosing, and target volume varied across studies. Among 13 studies that included only non-BOS tumors or separately grouped non-BOS tumors, symptomatic edema occurred in 5% to 43% of patients and any edema occurred in 28% to 50%. The reported average time to onset of edema ranged from approximately 3 to 9 months in most studies. Factors reported to significantly correlate with increased risks of edema and/or symptomatic edema after SRS for meningioma include the following: greater tumor margin and/or maximum dose, greater tumor size and/or volume, non-BOS (particularly parasagittal) location, no prior resection for meningioma, and presence of pretreatment edema. Nevertheless, the extent and significance of these factors were inconsistent across studies. Potentially important dosimetric factors, such as volume of brain or tissue receiving single-fraction doses > 10 to 12 Gy, are not well studied. CONCLUSIONS: The variability in risks of edema and in factors impacting those risks is likely a result of differences across studies in the clinicopathologic characteristics of the patient populations, as well as differences in treatment modalities and SRS planning and delivery parameters. More studies on pooled populations, grouped by potential prognostic factors such as tumor location and prior therapy, are needed to better understand dosimetric and nondosimetric factors predictive of edema risk after SRS for meningioma.
Authors: Keenan Piper; Siyuan Yu; Mohammad Taghvaei; Christian Fernandez; Nikolaos Mouchtouris; Rupert D Smit; Clifford Yudkoff; Sarah Collopy; Maikerly Reyes; Pascal Lavergne; Michael Karsy; Giyarpuram N Prashant; Wenyin Shi; James Evans Journal: Front Surg Date: 2022-07-04
Authors: Austin M Tang; Joshua Bakhsheshian; Michelle Lin; Casey A Jarvis; Edith Yuan; Ian A Buchanan; Li Ding; Ben A Strickland; Eric Chang; Gabriel Zada; William J Mack; Frank J Attenello Journal: J Radiosurg SBRT Date: 2019
Authors: Daniel Rueß; Vera Weyer; Juman Tutunji; Stefan Grau; Martin Kocher; Mauritius Hoevels; Harald Treuer; Christian Baues; Maximilian I Ruge Journal: Radiat Oncol Date: 2020-12-09 Impact factor: 3.481
Authors: Sang Mook Kang; Jae Min Kim; Jin Hwan Cheong; Je Il Ryu; Yu Deok Won; Young Soo Kim; Myung-Hoon Han Journal: Radiat Oncol Date: 2021-08-23 Impact factor: 3.481
Authors: Michael T Milano; Jimm Grimm; Andrzej Niemierko; Scott G Soltys; Vitali Moiseenko; Kristin J Redmond; Ellen Yorke; Arjun Sahgal; Jinyu Xue; Anand Mahadevan; Alexander Muacevic; Lawrence B Marks; Lawrence R Kleinberg Journal: Int J Radiat Oncol Biol Phys Date: 2020-09-11 Impact factor: 8.013